Annovis Bio AI Stock Analysis
Want to see ANVS full AI Analyst Report?
Annovis Bio (ANVS) AI Stock Analysis
Annovis Bio
(NYSE:ANVS)
The score is primarily dragged down by weak financial fundamentals typical of a pre-revenue biotech—ongoing losses, sustained cash burn, and especially the reported TTM negative equity—along with a technically weak trend (trading below major moving averages with negative MACD). Corporate-event risk is elevated due to NYSE non-compliance/delisting risk, while valuation signals are not supportive given a negative P/E and no dividend.
Annovis Bio (ANVS) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $32.01M
- Dividend Yield
- ―
- Average Volume (3M)
- 1.75M
- Price to Earnings (P/E)
- -0.5
- Beta (1Y)
- 2.63
- Revenue Growth
- ―
- EPS Growth
- -15.00%
- Country
- US
- Employees
- 7
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
Annovis Bio Business Overview & Revenue Model
Company Description
Annovis Bio, Inc. is a clinical-stage biopharmaceutical company focused on pioneering treatments for neurodegenerative disorders. The firm's flagship drug, Buntanetap, an oral medication, has successfully advanced through Phase 2a clinical trials for...
Annovis Bio Financial Statement Overview
Summary
Clinical-stage, pre-revenue profile with persistent, material losses and cash burn (TTM EBIT about -$59.1M; TTM operating cash flow about -$55.9M). While the company reports zero debt, the provided data shows a highly concerning TTM negative stockholders’ equity (approximately -$13.23B) and notable equity volatility, which materially weakens the financial risk profile.
Income Statement
9Very NegativeBalance Sheet
12Very NegativeCash Flow
14Very Negative| Breakdown | TTM | Dec 2025 | Mar 2025 | Mar 2024 | Mar 2023 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0 | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 | 0 | 0 | 0 |
| EBITDA | -58.79M | -28.85M | -22.74M | -56.20M | -25.33M | -14.50M |
| Net Income | -51.72M | -28.85M | -24.59M | -56.20M | -25.33M | -14.49M |
Balance Sheet | ||||||
| Total Assets | 5.50B | 21.08M | 13.93M | 10.21M | 36.02M | 46.00M |
| Cash, Cash Equivalents and Short-Term Investments | 2.82B | 19.53M | 10.55M | 5.75M | 28.38M | 45.69M |
| Total Debt | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Liabilities | 18.74B | 4.23M | 4.62M | 17.96M | 7.70M | 1.51M |
| Stockholders Equity | -13.23B | 16.85M | 9.31M | -7.75M | 28.32M | 44.49M |
Cash Flow | ||||||
| Free Cash Flow | -55.89M | -25.62M | -21.89M | -39.97M | -17.31M | -9.13M |
| Operating Cash Flow | -55.89M | -25.62M | -21.89M | -39.97M | -17.31M | -9.13M |
| Investing Cash Flow | 0 | 0 | 0 | 0 | 0 | 0 |
| Financing Cash Flow | 43.42M | 34.60M | 26.69M | 17.34M | 4,613 | 46.74M |
Annovis Bio Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ANVS, the sentiment is Negative. The current price of 0.75 is below the 20-day moving average (MA) of 0.96, below the 50-day MA of 1.09, and below the 200-day MA of 1.80, indicating a bearish trend. The MACD of -0.08 indicates Positive momentum. The RSI at 38.28 is Neutral, neither overbought nor oversold. The STOCH value of 33.57 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for ANVS.
Annovis Bio Risk Analysis
Annovis Bio disclosed 77 risk factors in its most recent earnings report. Annovis Bio reported the most risks in the "Tech & Innovation" category.
Latest Risks Added
3 New RisksAnnovis Bio Peers Comparison
Overall Rating
DTIL58Neutral
COYA43Neutral
ANVS42Neutral
WHWK40Underperform
ABOS38Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 58Neutral | $203.37M | -5.97 | -58.09% | ― | 6353.01% | 84.80% | |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| 43Neutral | $70.37M | -2.17 | -71.48% | ― | 17.59% | -20.34% | |
| 42Neutral | $32.01M | -0.48 | 1.57% | ― | ― | -15.00% | |
| 40Underperform | $177.62M | -2.75 | -55.66% | ― | -100.00% | -825.52% | |
| 38Underperform | $15.62M | -0.14 | -166.49% | ― | ― | 29.92% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| ANVS | Annovis Bio Inc | 0.75 | -2.62 | -77.74% | |
| WHWK | Whitehawk Therapeutics, Inc. | 3.01 | 0.87 | 40.65% | |
| DTIL | Precision Biosciences | 7.28 | 2.06 | 39.46% | |
| GLSI | Greenwich Lifesciences, Inc. | 13.76 | 5.52 | 66.99% | |
| ABOS | Acumen Pharmaceuticals, Inc. | 0.22 | -1.44 | -86.99% | |
| COYA | Coya Therapeutics, Inc. | 3.00 | -3.16 | -51.30% |
Annovis Bio Corporate Events
Annovis Bio Announces Pricing of Public Offering and Underwriting Agreement
NeutralOn November 4, 2026, Annovis Bio announced the launch of a public offering, and on November 5, 2026, it entered an underwriting agreement and announced the offering’s pricing. The offering comprised 19 million common shares or pre-funded warrants for...
Annovis Bio Files Charter Amendment After Stockholder Approval
NeutralOn November 3, 2026, Annovis Bio stockholders approved increasing authorized common shares from 70 million to 140 million and ratified an amendment increasing shares authorized under the company’s 2019 Equity Incentive Plan. The company filed the cha...
Annovis Bio Clarifies Regulation FD Disclosure in Current Report
NeutralAnnovis Bio, Inc. said previously disclosed information was incorporated by reference into additional sections of its current report, while clarifying the information was furnished rather than filed under securities-law provisions unless specifically...
Annovis Bio Addresses NYSE Non-Compliance Listing Notice
NegativeOn October 29, 2026, Annovis Bio received notice from the New York Stock Exchange that it had fallen out of compliance with continued listing standards because its 30-day average market capitalization and stockholders’ equity were both below the $50...
Annovis Bio Updates Audit Fee Disclosure for Transparency
PositiveAnnovis Bio disclosed that, due to a typographical error in its proxy statement for the annual meeting of stockholders held on June 17, 2026, it has corrected the previously reported audit fee information. The updated figures show that Ernst & Young...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 15, 2026
